Each vial contains 5 mg of CJC-1295 (no DAC) and 5 mg of Ipamorelin in a 1:1 ratio, in lyophilized form.
CJC-1295 without DAC, also known as modified GRF(1-29), is a synthetic 29-amino-acid GHRH analogue carrying four amino acid substitutions that resist enzymatic degradation. Ipamorelin is a synthetic pentapeptide acting as a selective agonist at the growth hormone secretagogue receptor (ghrelin receptor).
The two sequences act at distinct receptors and are studied together for their combined effect on growth hormone release. Ipamorelin is noted in the literature for its receptor selectivity, with limited reported effect on cortisol and prolactin relative to earlier secretagogues. The short half-life of the non-DAC form makes this pairing a common choice in studies of pulsatile rather than sustained secretion.
Areas of published research
- Growth hormone pulse amplitude and frequency following combined GHRH receptor and ghrelin receptor activation
- Downstream IGF-1 expression as a marker of growth hormone axis activity
- Receptor selectivity of Ipamorelin, with reported minimal effect on cortisol and prolactin relative to earlier secretagogues
- Pulsatile versus sustained secretion patterns, using the short half-life of the non-DAC form
For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.


Reviews
There are no reviews yet.